ETX — E-Therapeutics Income Statement
0.000.00%
Last trade - 00:00- £54.93m
- £23.53m
- £0.48m
Annual income statement for E-Therapeutics, fiscal year end - January 31st, GBP millions except per share, conversion factor applied.
2021 January 31st | 2022 January 31st | 2023 January 31st | 2024 January 31st | 2025 January 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.317 | 0.477 | 0.475 | 0.318 | 0 |
| Cost of Revenue | |||||
| Gross Profit | 0.317 | 0.477 | 0.475 | 0.318 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Total Operating Expenses | 4.8 | 10 | 10.7 | 14.1 | 18.6 |
| Operating Profit | -4.49 | -9.57 | -10.2 | -13.8 | -18.6 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -4.47 | -9.52 | -9.77 | -13.1 | -17.6 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -3.68 | -8.07 | -8.27 | -11.2 | -14.9 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -3.68 | -8.07 | -8.27 | -11.2 | -14.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -3.68 | -8.07 | -8.27 | -11.2 | -14.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.01 | -0.016 | -0.015 | -0.019 | -0.02 |